Besides these new avenues of investigation, the important clinical implication of this work is to provide supportive rationale to blocking the fatty acid metabolic pathway in EGFR mutant NSCLC patients, notably in non‐responders and/or in those who developed resistance to anti‐EGFR therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.